Biohacking Research Roundup: Most-Searched Compounds & Emerging Research Q2 2026

Q2 2026 research roundup: retatrutide momentum, MOTS-c aging research, Semax and Selank growth, berberine GLP-1 demand, and emerging dual-targeting peptide themes.

TL;DR

• Retatrutide Phase 2 data showing 24% weight loss at 48 weeks has made it the most-watched metabolic compound in development.
• MOTS-c is emerging as a genuine longevity biomarker and research target, backed by credible US academic research.
• Semax and Selank searches are growing as cognitive peptide research interest expands beyond performance circles.
• Berberine demand is surging on the back of GLP-1 interest — the mechanism is related but not equivalent.

Disclaimer: For educational and research purposes only — not medical advice. Emerging research is by definition preliminary — calibrate confidence accordingly.

The research landscape in performance biology, longevity, and metabolic health is moving quickly. Q2 2026 is marked by continued momentum from GLP-1 class compounds at the pharmaceutical level, growing interest in mitochondrial biology at the longevity frontier, and expanding searches for cognitive peptides in the performance space. This roundup covers the most-searched compounds, what the actual research says, and where the line sits between established science and speculative hype.

Retatrutide: The Triple Agonist Transforming Weight Loss Research

Retatrutide (LY3437943) is Eli Lilly's next-generation metabolic compound, designed as a tripartite agonist at three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple mechanism extends beyond tirzepatide's dual GIP/GLP-1 approach by adding glucagon receptor activation, which drives hepatic fat oxidation and thermogenesis.

The Phase 2 trial data (Jastreboff et al., 2023, NEJM) enrolled 338 adults with obesity and no diabetes. At the highest dose tested (12mg weekly), mean weight loss was:

• At 24 weeks: 17.5% body weight reduction
• At 48 weeks: 24.2% body weight reduction

This 24% figure represents the largest pharmacological weight loss effect ever published in a clinical trial. For context: semaglutide 2.4mg (Wegovy) produced ~15% in STEP trials; tirzepatide (Mounjaro) produced ~20% in SURMOUNT-1. Retatrutide appears to meaningfully exceed both.

What makes the triple agonism different from dual agonism: The glucagon receptor component increases hepatic glucose production and fat oxidation in the liver — a potential benefit for fatty liver disease — but also carries a theoretical risk of worsening glycemia in diabetic populations. The GIP and GLP-1 components likely compensate via insulin secretion enhancement, keeping glucose under control. Phase 3 trials (TRIUMPH program) are ongoing as of early 2026.

Research community interest: The retatrutide search surge reflects both Phase 3 progression anticipation and growing awareness of triple agonism as a design principle being extended to other compound classes. Dual GLP-1/glucagon peptides and GLP-1/GIPR antagonism combinations are in development by multiple pharmaceutical companies.

MOTS-c: The Mitochondrial Peptide Hormone in Aging Research

MOTS-c is a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene — making it one of a very small class of peptides (mitokines) encoded by the mitochondrial genome. Its discovery by Changhan David Lee and Pinchas Cohen at USC in 2015 opened a new branch of mitochondrial biology research: the idea that mitochondria communicate with the nucleus and other tissues via secreted signaling peptides.

Key research findings:

• MOTS-c circulates in human plasma and declines significantly with age (Lee et al., 2015, Cell Metabolism)
• In mice, systemic MOTS-c administration increased lifespan, improved physical fitness, and reversed diet-induced obesity and insulin resistance
• A 2021 Nature Communications study (Kim et al.) found that low circulating MOTS-c levels in humans are associated with age-related metabolic disease in a cohort study
• Under exercise stress, MOTS-c translocates to the nucleus and modulates the expression of stress response and metabolic genes
• MOTS-c directly activates AMPK and the AICAR (adenosine analog) pathway, improving glucose uptake independent of insulin

Why the research community is paying attention: MOTS-c represents a genuinely novel mechanism — not another variation on existing metabolic compound classes. Its mitochondrial origin means it sits at the intersection of mitochondrial aging, metabolic regulation, and longevity biology in a way that few other compounds do. The USC group's research is conducted at a credible US academic institution with full peer review, which distinguishes it from some longevity peptide research that originates from less-verified sources.

Current research status: No clinical trials in human healthy aging populations have been completed. Most data is from cell culture and rodent models. The compound exists in the research use only space. See the MOTS-c database entry for the full citation summary.

Semax and Selank: Cognitive Peptides With Growing Research Interest

Semax and Selank are synthetic peptide nootropics developed in Russia at the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology, respectively. Both have been approved as drugs in Russia for specific neurological indications; both are now increasingly searched by Western performance and biohacking researchers.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a ACTH(4–7)PGP heptapeptide that stimulates BDNF and NGF synthesis, modulates dopaminergic and serotonergic systems, and has demonstrated neuroprotective effects in stroke models. Its growing popularity in the West relates to:

• BDNF-mediated learning enhancement and neuroplasticity
• Motivation and drive effects attributed to dopaminergic modulation
• Nasal spray administration providing CNS access without injection

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a tuftsin analog with anxiolytic and immunomodulatory properties. Its mechanism involves GABAergic modulation, BDNF elevation, and IL-6 regulation. The primary research interest from athletes and performance researchers involves:

• Anxiety and stress reduction without sedation (relevant to competition preparation)
• HPA axis modulation reducing cortisol reactivity
• Potential cognitive enhancement under stress conditions

See the Selank database entry for detailed research citations.

Search trend analysis suggests a significant increase in English-language searches for both compounds starting in mid-2024 and continuing through 2026 — driven partly by social media discussion in biohacking communities and partly by the general expansion of peptide research awareness.

Berberine: The Most Searched GLP-1 "Alternative"

Berberine is an isoquinoline alkaloid derived from plants including Berberis aristata and Coptis chinensis. It has been used in traditional Chinese medicine for centuries and has accumulated a substantial modern research base in metabolic health.

What berberine actually does (mechanism):

• Primary mechanism: AMPK activation, mimicking the cellular energy-sensing state induced by exercise and caloric restriction
• Secondary mechanisms: Inhibition of intestinal α-glucosidase (reducing post-meal glucose), upregulation of insulin receptor expression, modulation of gut microbiome (reducing Firmicutes/Bacteroidetes ratio)
• GLP-1 connection: Berberine increases GLP-1 secretion from intestinal L-cells by approximately 1.5–2x in animal studies. This is an indirect GLP-1-elevating effect, not direct receptor agonism.

Human evidence: A 2008 meta-analysis in Metabolism (Yin et al.) found berberine comparable to metformin for blood glucose reduction in type 2 diabetes RCTs. Multiple subsequent studies have confirmed HbA1c reductions of 0.5–1.0% and LDL cholesterol reductions of 15–20%. A 2023 meta-analysis (Li et al., Frontiers in Pharmacology) confirmed benefits on metabolic markers across 27 RCTs.

The "nature's Ozempic" framing is misleading. Berberine does not achieve the 15–24% weight loss seen with pharmaceutical GLP-1 agonists. The weight loss data for berberine is modest: most studies show 2–5% body weight reduction. The mechanism is overlapping with GLP-1 pharmacology in some respects but not equivalent in magnitude.

Research dose: 500mg, 2–3x daily with meals (AMPK activation is meal-dependent for optimal effect). Bioavailability is limited but self-limiting — nanoformulated berberine shows improved absorption but remains under investigation.

Emerging Research Themes: Oral Peptide Delivery and Combination Longevity Protocols

Two thematic shifts in the research literature are worth tracking as they will define the next generation of performance and longevity compound development.

Oral peptide delivery: The challenge of oral peptide bioavailability (described in the Peptide vs Small Molecule article) is now an active pharmaceutical engineering focus. Approaches being researched include:

• SNAC technology: Used in oral semaglutide (Rybelsus), sodium N-[8-(2-hydroxybenzoyl)aminocaprylate] protects GLP-1 analog from proteolysis and enhances epithelial absorption
• Cyclic peptides: Structural constraint reduces conformational flexibility and improves membrane permeability (Cyclosporine A model)
• Lipid nanoparticle encapsulation: LNP technology developed for mRNA vaccines is now being applied to peptide oral delivery
• PEGylation and fatty acid conjugation: Extended half-life modifications that may improve oral stability profiles

If oral peptide delivery is solved at scale, it removes the primary practical barrier to widespread performance peptide research — the requirement for injection.

Combination longevity protocols: The longevity research community is increasingly moving toward multi-target protocols that combine NAD+ precursors, senolytics, mTOR inhibition (rapamycin is under active investigation), and mitochondrial support. A 2024 pre-print from the Interventions Testing Program (ITP) — a highly respected murine longevity testing program — reported synergistic lifespan extension from combining rapamycin with NAD+ precursors, greater than either compound alone. This kind of combinatorial longevity research is beginning to inform human research protocol design.

Summary: Evidence Calibration by Compound

Frequently Asked Questions

Q: Is retatrutide available for research yet? A: As of Q2 2026, retatrutide is in Phase 3 clinical trials (the TRIUMPH program). It is not FDA-approved and does not have an approved status in any major jurisdiction. Some research peptide suppliers have begun offering research-grade retatrutide as a RUO compound, subject to the same regulatory considerations as other unapproved research peptides. The compound's Phase 3 data readout is anticipated in late 2026 to 2027.

Q: What is the relationship between MOTS-c and exercise? A: Exercise is one of the most potent natural stimulators of MOTS-c production. During physical stress, MOTS-c is upregulated in skeletal muscle and secreted into circulation, where it acts as an exercise-induced signal to other tissues. This positions MOTS-c as part of the molecular explanation for why exercise produces systemic metabolic benefits — the "exercise hormone" concept. For longevity researchers, this also suggests that sufficient exercise is a prerequisite for any MOTS-c research protocol, and that exogenous MOTS-c may be most relevant in aging populations where exercise-induced MOTS-c secretion is blunted.

Q: Should berberine be cycled or taken continuously? A: The published RCT literature has used continuous berberine supplementation for 3–6 months without reporting downregulation of efficacy. AMPK activation by berberine does not appear to develop tolerance in the available data. However, berberine is a potent inhibitor of CYP3A4 and CYP2D6 hepatic enzymes, meaning it can significantly affect the metabolism of other compounds taken simultaneously. Researchers using berberine alongside other compounds should check for known CYP enzyme interactions. Some practitioners cycle berberine (5 days on, 2 days off) to reduce cumulative CYP inhibition, though this is not supported by specific RCT evidence.

Q: What cognitive peptides beyond Semax and Selank are being researched? A: Dihexa (PNB-0408), a hepatocyte growth factor (HGF) potentiator, has attracted significant interest for its reported synaptic density increases and cognitive performance effects in animal models — reported to be magnitudes more potent than BDNF per se. NSI-189 is a synthetic compound (not a peptide) studied for neurogenesis. Epithalon (primarily studied for pineal and longevity effects) has secondary data on cognitive preservation. P21 is a CNTF-derived peptide with some laboratory cognitive enhancement data. The cognitive peptide research space is early-stage and the quality of evidence varies significantly across compounds. See the nootropics research section for more detail.

Explore specific compound profiles across the database. → Browse the Peptide Database

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions